Patent details

Basic Information

Publication number:

EP3665196

PCT Application Number:

EP2018071462

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP187554217

PCT Publication Number:

WO2019030260

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

OBINUTUZUMAB TREATMENT OF A DLBCL PATIENT SUBGROUP

French Title of Invention:

OBINUTUZUMAB TRAITEMENT D'UN SOUS-GROUPE DE PATIENTS LMNH

German Title of Invention:

OBINUTUZUMAB BEHANDLUNG VON PATIENTEN EINER DLBCL UNTERGRUPPE

SPC Number:

Dates

Filing date:

08/08/2018

Grant date:

19/10/2022

EP Publication Date:

17/06/2020

PCT Publication Date:

14/02/2019

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

19/10/2022

EP B1 Publication Date:

19/10/2022

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

08/08/2023

Expiration date:

08/08/2038

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

12/10/2022

 

 

Name:

F. Hoffmann-La Roche AG

Address:

Grenzacherstrasse 124, 4070 Basel, Switzerland (CH)

Name:

NanoString Technologies, Inc.

Address:

530 Fairview Ave North, Seattle, WA 98109, United States (US)

Inventor

Name:

OESTERGAARD, Mikkel Zahle

Address:

Switzerland (CH)

Priority

Priority Number:

201762542489 P

Priority Date:

08/08/2017

Priority Country:

United States (US)

Classification

IPC classification:

C07K 16/28; A61K 39/395;

Publication

European Patent Bulletin

Issue number:

202242

Publication date:

19/10/2022

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages